Ocugen, Inc. Announces Closing of $23 Million Registered Direct Offering of Common Stock

Ocugen公司宣布完成2300万美元注册直接发行普通股

2021-02-11 18:30:08 BioSpace

本文共1442个字,阅读需4分钟

MALVERN, Pa., Feb. 10, 2021 -- Ocugen, Inc.,  , a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19, today announced that it has closed the previously announced registered direct offering for the sale of an aggregate of 3,000,000 shares of its common stock for gross proceeds of approximately $23 million, prior to deducting placement agent’s fees and other offering expenses payable by Ocugen. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Ocugen intends to use the net proceeds from the offering for general corporate purposes, capital expenditures, working capital and general and administrative expenses. The shares of common stock described above were offered pursuant to a “shelf” registration statement (File No. 333-237456) filed with the Securities and Exchange Commission (“SEC”) on March 27, 2020 and declared effective on May 5, 2020. Such shares of common stock were offered only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. A final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock was filed with the SEC. Electronic copies of the final prospectus supplement and the accompanying prospectus relating to the offering of the shares of common stock may be obtained on the SEC’s website at http://www.sec.gov or by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by e-mail: placements@hcwco.com or by telephone: (646) 975-6996. This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Ocugen, Inc. Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to fight COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug – “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. For more information, please visit www.ocugen.com. Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. Such forward-looking statements within this press release include, without limitation, the intended use of net proceeds from the registered direct offering. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations, such as market and other conditions. These and other risks and uncertainties are more fully described in our periodic filings with the SEC, including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events or otherwise, after the date of this press release. Corporate Contact: Ocugen, Inc. Sanjay Subramanian Chief Financial Officer and Head of Corporate Development IR@Ocugen.com Media Contact: LaVoieHealthScience Emmie Twombly etwombly@lavoiehealthscience.com +1 857-389-6042
2021年2月10日,宾夕法尼亚州马尔文--生物制药公司Ocugen公司专注于发现、开发和商业化治疗失明疾病的基因疗法,并开发抗击COVID-19的疫苗,今天宣布,它已经完成了之前宣布的注册直接发行,出售总计300万股普通股,总收益约2300万美元,之前扣除配售代理费用和Ocugen应支付的其他发行费用。 H.C.Wainwright公司是本次发行的独家代理。 Ocugen拟将发售所得款项净额用作一般公司用途、资本开支、营运资金及一般及行政开支。 上述普通股股份根据于2020年3月27日向美国证券交易委员会(“SEC”)提交并于2020年5月5日宣布生效的“上架”登记表(文件号333-237456)发行。这类普通股仅通过招股说明书(包括招股说明书补充说明)的方式发售,该招股说明书是有效注册声明的一部分。一份最终的招股说明书补充文件以及与发行普通股有关的附带招股说明书已向SEC提交。有关普通股发行的最终招股说明书补充说明和随附招股说明书的电子副本可在SEC网站http://www.sec.gov上获得,也可与H.C.联系。Wainwright&Co.,LLC地址:纽约州纽约市公园大道430号3楼,邮编:10022,电子邮件:placements@hcwco.com或电话:(646)975-6996。 本新闻稿不应构成出售或征求购买这些证券的要约,也不应在任何州或其他司法管辖区销售这些证券,如果在该州或其他司法管辖区根据任何此类州或其他司法管辖区的证券法注册或资格之前,该要约、征求或销售是非法的。 关于Ocugen公司。 Ocugen公司是一家生物制药公司,专注于发现、开发和商业化治疗失明疾病的基因疗法,并开发抗击COVID-19的疫苗。我们突破性的修饰基因治疗平台具有用一种药物治疗多种视网膜疾病的潜力--“一对多”,而我们的新型生物候选产品旨在为缺乏服务的疾病患者提供更好的治疗,如湿性年龄相关性黄斑变性、糖尿病性黄斑水肿和糖尿病性视网膜病变。欲了解更多信息,请访问www.ocugen.com。 关于前瞻性陈述的警告性说明 本新闻稿包含1995年私人证券诉讼改革法案含义范围内的前瞻性陈述,这些陈述受到风险和不确定性的影响。本新闻稿中的此类前瞻性陈述包括但不限于注册直接发行所得净收益的预期用途。在某些情况下,我们可以使用诸如“预测”、“相信”、“潜在”、“提议”、“继续”、“估计”、“预期”、“预期”、“计划”、“打算”、“可能”、“能够”、“可能”、“将”、“应该”等术语或其他表达未来事件或结果不确定性的词语来识别这些前瞻性陈述。这类陈述受到许多重要因素、风险和不确定因素的影响,这些因素可能导致实际事件或结果与我们当前的预期有重大差异,如市场和其他条件。这些及其他风险和不确定性在我们定期向SEC提交的文件中有更全面的描述,包括我们向SEC提交的季度和年度报告中题为“风险因素”一节中描述的风险因素。我们在本新闻稿中所作的任何前瞻性陈述仅限于本新闻稿发布之日。除法律要求外,我们没有义务更新本新闻稿中包含的前瞻性陈述,无论是由于新信息、未来事件或其他原因,在本新闻稿发布之日后。 公司联系人: 奥库根公司。 桑贾伊·苏布拉马尼安 首席财务官兼公司发展主管 @ocugen.com 媒体联系人: LavoieHealthScience 艾米·托姆布莱 @lavoiehealthscience.com +1 857-389-6042

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文